| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1995;60:789-792
© 1995 The Society of Thoracic Surgeons
Cardiovascular Pharmacology, Upjohn Laboratories, The Upjohn Company, Kalamazoo, Michigan
Abstract
Background. The angiotensin-converting enzyme inhibitor ramiprilat has been previously demonstrated to protect myocardium from ischemia/reperfusion injury. The objective of these investigations was to examine the roles of bradykinin, angiotensin II, and nitric oxide in the cardioprotective effects of ramiprilat.
Methods. Anesthetized, open-chest rabbits were instrumented for production of myocardial ischemia (30 minutes) and subsequent reperfusion (120 minutes), after which myocardial infarct size was measured. Animals were treated intravenously with either saline solution, ramiprilat (50 µg/kg), the bradykinin2 receptor antagonist HOE 140 (1 µg/kg), ramiprilat + HOE 140, angiotensin II (2.5 ng • kg-1 • min-1), the angiotensin II receptor antagonist losartan (20 mg/kg), ramiprilat + angiotensin II, the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (100 µg • kg-1 • min-1), or ramiprilat + NG-nitro-L-arginine methyl ester.
Results. Among all treatment groups myocardial infarct size was reduced significantly below saline control only by ramiprilat (-54%) and ramiprilat + angiotensin II (-37%). Pretreatment with HOE 140 or NG-nitro-L-arginine methyl ester abolished the cardioprotective effect of ramiprilat. Neither stimulation nor antagonism of angiotensin II receptors altered infarct size from the saline control level. Also, when isolated neonatal rat cardiomyocytes were exposed to hypoxia/reoxygenation, ramiprilat (100 µmol/L) and bradykinin (10 nmol/L) improved cell viability (
60%), and the protective effect of both agents was reversed by administration of HOE 140 (10 µmol/L).
Conclusions. These results indicate that the in vivo cardioprotective effect of ramiprilat can be abolished by antagonizing bradykinin receptors or inhibiting nitric oxide synthase, and that the effect is not related to angiotensin II receptor activity. The potential bradykinin-sparing property of ramiprilat may promote increased bradykinin-stimulated nitric oxide production leading to cardioprotection. Part of the cardioprotective effects of ramiprilat/bradykinin/nitric oxide may occur locally as demonstrated by the in vitro results using isolated cardiomyocytes.
This article has been cited by other articles:
|
|
 |
|
  E. Messadi-Laribi, V. Griol-Charhbili, A. Pizard, M.-P. Vincent, D. Heudes, P. Meneton, F. Alhenc-Gelas, and C. Richer Tissue Kallikrein Is Involved in the Cardioprotective Effect of AT1-Receptor Blockade in Acute Myocardial Ischemia J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 210 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Lazar Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient Ann. Thorac. Surg., March 1, 2005; 79(3): 1081 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J Hausenloy and D. M Yellon New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway Cardiovasc Res, February 15, 2004; 61(3): 448 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-M. Yu, G. L. Tipoe, K. Wing-Hon Lai, and C.-P. Lau Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1207 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lazar, Y. Bao, S. Rivers, T. Colton, and S. A. Bernard High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size Ann. Thorac. Surg., August 1, 2001; 72(2): 548 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-q. Zhu, Y.-p. Sun, R. E Sievers, A. E. Browne, R. J Lee, K. Chatterjee, and W. W Parmley Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2): 129 - 133. [Abstract] [PDF]
|
|
|
|
|
|
B.-q. Zhu, Y.-p. Sun, R. E. Sievers, A. E. M. Browne, S. Pulukurthy, K. Sudhir, R. J. Lee, T. M. Chou, K. Chatterjee, and W. W. Parmley Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion J. Am. Coll. Cardiol., March 1, 2000; 35(3): 787 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kobayashi, T. Higashi, K. Hara, H. Shirataki, and H. Matsuoka Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats Cardiovasc Res, December 1, 1999; 44(3): 518 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shigematsu, S. Ishida, D. C. Gute, and R. J. Korthuis Concentration-dependent effects of bradykinin on leukocyte recruitment and venular hemodynamics in rat mesentery Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H152 - H160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shigematsu, S. Ishida, D. C. Gute, and R. J. Korthuis Bradykinin prevents postischemic leukocyte adhesion and emigration and attenuates microvascular barrier disruption Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H161 - H171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-P. Yang, Y.-H. Liu, E. G. Shesely, M. Bulagannawar, F. Liu, and O. A. Carretero Endothelial Nitric Oxide Gene Knockout Mice : Cardiac Phenotypes and the Effect of Angiotensin-Converting Enzyme Inhibitor on Myocardial Ischemia/Reperfusion Injury Hypertension, July 1, 1999; 34(1): 24 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matoba, T. Tatsumi, N. Keira, A. Kawahara, K. Akashi, M. Kobara, J. Asayama, and M. Nakagawa Cardioprotective Effect of Angiotensin-Converting Enzyme Inhibition Against Hypoxia/Reoxygenation Injury in Cultured Rat Cardiac Myocytes Circulation, February 16, 1999; 99(6): 817 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Ritchie, R. J. Schiebinger, M. C. Lapointe, and J. D. Marsh Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1370 - H1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lazar, C. Volpe, Y. Bao, S. Rivers, J. A. Vita, and J. F. Keaney Jr Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization Ann. Thorac. Surg., August 1, 1998; 66(2): 487 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Ritchie, J. D. Marsh, W. D. Lancaster, C. A. Diglio, and R. J. Schiebinger Bradykinin Blocks Angiotensin II-Induced Hypertrophy in the Presence of Endothelial Cells Hypertension, January 1, 1998; 31(1): 39 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
J. B. Laursen and D. G. Harrison Modulation of Myocardial Oxygen Consumption Through ACE Inhibitors: NO Effect? Circulation, January 7, 1997; 95(1): 14 - 16. [Full Text]
|
|
|
|
 |
|
 A. Horstmeyer, H. Cramer, T. Sauer, W. Muller-Esterl, and C. Schroeder Palmitoylation of Endothelin Receptor A. DIFFERENTIAL MODULATION OF SIGNAL TRANSDUCTION ACTIVITY BY POST-TRANSLATIONAL MODIFICATION J. Biol. Chem., August 23, 1996; 271(34): 20811 - 20819. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
